SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2025
Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
EXHIBIT
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | |||||||||||
| Date: March 26, 2025 | By: | /s/ Norimasa Takeda | |||||||||
Norimasa Takeda Chief Accounting Officer and Corporate Controller | |||||||||||
News Release
Takeda Announces Candidates for Board of Directors
at Upcoming Shareholders Meeting
at Upcoming Shareholders Meeting
OSAKA, Japan and CAMBRIDGE, Massachusetts, March 26, 2025 - Takeda (TSE:4502/NYSE:TAK) announced its Board of Directors decided today to propose the re-election of all current directors (excluding Audit and Supervisory Committee Members) at the 149th Ordinary General Meeting of Shareholders on June 25, 2025.
Candidates for Directors Who Are Not Audit and Supervisory Committee Members
Name | Category | Expected Role | |||||||||
Christophe Weber | Internal | Existing | Representative Director, President & Chief Executive Officer | ||||||||
Milano Furuta | Internal | Existing | Director, Chief Financial Officer | ||||||||
Andrew Plump | Internal | Existing | Director, President, Research & Development | ||||||||
Masami Iijima | External | Existing | External Director, Chair of the Board Meeting | ||||||||
Ian Clark | External | Existing | External Director | ||||||||
Steven Gillis | External | Existing | External Director | ||||||||
Emiko Higashi | External | Existing | External Director | ||||||||
John Maraganore | External | Existing | External Director | ||||||||
Michel Orsinger | External | Existing | External Director | ||||||||
Miki Tsusaka | External | Existing | External Director | ||||||||
The tenure for non-Audit and Supervisory Committee director is one year.
The following four Directors who are Audit and Supervisory Committee members were elected at the 148th Ordinary General Meeting of Shareholders held in 2024 and their terms of office will continue until the 150th Ordinary General Meeting of Shareholders held in 2026.
Name | Category | Role | ||||||
Koji Hatsukawa | External | External Director, Head of Audit and Supervisory Committee | ||||||
Jean-Luc Butel | External | External Director, Audit and Supervisory Committee Member | ||||||
Yoshiaki Fujimori | External | External Director, Audit and Supervisory Committee Member | ||||||
Kimberly A. Reed | External | External Director, Audit and Supervisory Committee Member | ||||||
The tenure for Audit and Supervisory Committee director is two years.
As announced last January 30*, Julie Kim, currently the president of the U.S. Business Unit and U.S. country head, will succeed Christophe Weber as Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Takeda’s Board of Directors will propose Mrs. Kim as a new candidate for election to the Board at the 150th Ordinary General Meeting of Shareholders to be held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.
* Please refer to “Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026”
Note:
1.The role of the directors who are not Audit and Supervisory Committee Members will be determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.
2.The members of the Nomination Committee and Compensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Media Contacts:
Global Media
Brendan Jennings
+81 80-2705-8259
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
###